Microarray analysis identifies IL-1 receptor type 2 as a novel candidate biomarker in patients with acute respiratory distress syndrome

Respiratory Research

Volumn 16, Issue 1, 2015, Pages

  Kovach, Melissa A ^a   Stringer, Kathleen A ^a,b   Bunting, Rachel ^c   Wu, Xiaoying ^c   San Mateo, Lani ^c   Newstead, Michael W ^a   Paine, Robert ^d   Standiford, Theodore J ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

^c CENTOCOR INC   (United States)

^d UNIVERSITY OF UTAH HEALTH SCIENCES CENTER   (United States)

Author keywords

Acute respiratory distress syndrome; Alveolar macrophage; Innate immunity; Microarray

Indexed keywords

ALPHA GLUCOSIDASE; AQUAPORIN 9; ARGINASE 1; CALCIUM BINDING PROTEIN; CALGRANULIN A; CD177 PROTEIN; CHEMOKINE RECEPTOR; CHEMOKINE RECEPTOR CCR2; CHEMOKINE RECEPTOR CXCR1; CXCL9 CHEMOKINE; DYSFERLIN; FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 13; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GELATINASE B; GLYCEROPHOSPHOINOSITOL INOSITOLPHOSPHODIESTERASE; HISTONE DEACETYLASE 4; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR TYPE II; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE 25; NEUTROPHIL COLLAGENASE; OLFACTOMEDIN 4; PAXILLIN; PROTEIN KINASE C BETA; RING FINGER PROTEIN; RING FINGER PROTEIN 175; S100 CALCIUM BINDING PROTEIN A12; UNCLASSIFIED DRUG; CALGRANULIN C; GENETIC MARKER; IL1R2 PROTEIN, HUMAN; S100A12 PROTEIN, HUMAN;

ADULT; ADULT RESPIRATORY DISTRESS SYNDROME; APACHE; ARTICLE; BLOOD; CELL METABOLISM; CELL POPULATION; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DOWN REGULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION; GENE IDENTIFICATION; GENETIC ASSOCIATION; HUMAN; IMMUNE RESPONSE GENE; IMMUNOLOGICAL TOLERANCE; LEUKOCYTE; LEUKOCYTE ACTIVATION; LUNG ALVEOLUS MACROPHAGE; MALE; MICROARRAY ANALYSIS; MIDDLE AGED; PATHOGENESIS; PHAGOCYTOSIS; PROTEIN BLOOD LEVEL; SURVIVOR; UPREGULATION; CASE CONTROL STUDY; DNA MICROARRAY; GENE EXPRESSION PROFILING; GENETIC MARKER; GENETICS; IMMUNOLOGY; MACROPHAGE ACTIVATION; METABOLISM; PILOT STUDY; PREDICTIVE VALUE; PROCEDURES; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPIRATORY DISTRESS SYNDROME, ADULT; SEVERITY OF ILLNESS INDEX;

ADULT; APACHE; CASE-CONTROL STUDIES; FEMALE; GENE EXPRESSION PROFILING; GENETIC MARKERS; HUMANS; LEUKOCYTES; MACROPHAGE ACTIVATION; MACROPHAGES, ALVEOLAR; MALE; MIDDLE AGED; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PILOT PROJECTS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTORS, INTERLEUKIN-1 TYPE II; RESPIRATORY DISTRESS SYNDROME, ADULT; S100A12 PROTEIN; SEVERITY OF ILLNESS INDEX;

EID: 84927731344     PISSN: 14659921     EISSN: 1465993X     Source Type: Journal    
DOI: 10.1186/s12931-015-0190-x     Document Type: Article

References (42)

1. Rubenfeld GD, Caldwell E, Peabody E, Weaver J, Martin DP, Neff M, et al. Incidence and outcomes of acute lung injury. N Engl J Med 2005, 353:1685-93. 10.1056/NEJMoa050333, 16236739.
2. Bernard GR, Artigas A, Brigham KL, Carlet J, Falke K, Hudson L, et al. The American-European Consensus Conference on ARDS. Definitions, mechanisms, relevant outcomes, and clinical trial coordination. Am J Respir Crit Care Med 1994, 149:818-24. 10.1164/ajrccm.149.3.7509706, 7509706.
3. Wheeler AP, Bernard GR. Acute lung injury and the acute respiratory distress syndrome: a clinical review. Lancet 2007, 369:1553-64. 10.1016/S0140-6736(07)60604-7, 17482987.
4. Bhatia M, Zemans RL, Jeyaseelan S. Role of chemokines in the pathogenesis of acute lung injury. Am J Respir Cell Mol Biol 2012, 46:566-72. 10.1165/rcmb.2011-0392TR, 22323365.
5. Meduri GU. The role of the host defence response in the progression and outcome of ARDS: pathophysiological correlations and response to glucocorticoid treatment. Eur Respir J 1996, 9:2650-70. 10.1183/09031936.96.09122650, 8980983.
6. Gordon S, Taylor PR. Monocyte and macrophage heterogeneity. Nat Rev Immunol 2005, 5:953-64. 10.1038/nri1733, 16322748.
7. Stout RD, Jiang C, Matta B, Tietzel I, Watkins SK, Suttles J. Macrophages sequentially change their functional phenotype in response to changes in microenvironmental influences. J Immunol 2005, 175:342-9. 10.4049/jimmunol.175.1.342, 15972667.
8. Gordon S, Fraser I, Nath D, Hughes D, Clarke S. Macrophages in tissues and in vitro. Curr Opin Immunol 1992, 4:25-32. 10.1016/0952-7915(92)90119-Y, 1317710.
9. MacKinnon AC, Farnworth SL, Hodkinson PS, Henderson NC, Atkinson KM, Leffler H, et al. Regulation of alternative macrophage activation by galectin-3. J Immunol 2008, 180:2650-8. 10.4049/jimmunol.180.4.2650, 18250477.
10. Hamilton JA, Tak PP. The dynamics of macrophage lineage populations in inflammatory and autoimmune diseases. Arthritis Rheum 2009, 60:1210-21. 10.1002/art.24505, 19404968.
11. Byers DE, Holtzman MJ. Alternatively activated macrophages and airway disease. Chest 2011, 140:768-74. 10.1378/chest.10-2132, 21896520.
12. Mages J, Dietrich H, Lang R. A genome-wide analysis of LPS tolerance in macrophages. Immunobiology 2007, 212:723-37. 10.1016/j.imbio.2007.09.015, 18086374.
13. Lyn-Kew K, Standiford TJ. Immunosuppression in sepsis. Curr Pharm Des 2008, 14:1870-81. 10.2174/138161208784980545, 18691098.
14. Deng JC, Cheng G, Newstead MW, Zeng X, Kobayashi K, Flavell RA, et al. Sepsis-induced suppression of lung innate immunity is mediated by IRAK-M. J Clin Invest 2006, 116:2532-42. 16917541.
15. Foster SL, Hargreaves DC, Medzhitov R. Gene-specific control of inflammation by TLR-induced chromatin modifications. Nature 2007, 447:972-8. 17538624.
16. Muller Kobold AC, Tulleken JE, Zijlstra JG, Sluiter W, Hermans J, Kallenberg CG, et al. Leukocyte activation in sepsis; correlations with disease state and mortality. Intensive Care Med 2000, 26:883-92. 10.1007/s001340051277, 10990102.
17. Munoz C, Carlet J, Fitting C, Misset B, Bleriot JP, Cavaillon JM. Dysregulation of in vitro cytokine production by monocytes during sepsis. J Clin Invest 1991, 88:1747-54. 10.1172/JCI115493, 1939659.
18. Hershman MJ, Cheadle WG, Wellhausen SR, Davidson PF, Polk HC. Monocyte HLA-DR antigen expression characterizes clinical outcome in the trauma patient. Br J Surg 1990, 77:204-7. 10.1002/bjs.1800770225, 2317682.
19. Adib-Conquy M, Adrie C, Fitting C, Gattolliat O, Beyaert R, Cavaillon JM. Up-regulation of MyD88s and SIGIRR, molecules inhibiting Toll-like receptor signaling, in monocytes from septic patients. Crit Care Med 2006, 34:2377-85. 10.1097/01.CCM.0000233875.93866.88, 16850005.
20. Ivashkiv LB. Inflammatory signaling in macrophages: transitions from acute to tolerant and alternative activation states. Eur J Immunol 2011, 41:2477-81. 10.1002/eji.201141783, 21952800.
21. Bethunaickan R, Berthier CC, Ramanujam M, Sahu R, Zhang W, Sun Y, et al. A unique hybrid renal mononuclear phagocyte activation phenotype in murine systemic lupus erythematosus nephritis. J Immunol 2011, 186:4994-5003. 10.4049/jimmunol.1003010, 21411733.
22. Mantovani A, Sica A. Macrophages, innate immunity and cancer: balance, tolerance, and diversity. Curr Opin Immunol 2010, 22:231-7. 10.1016/j.coi.2010.01.009, 20144856.
23. Binnie A, Tsang JL, dos Santos CC. Biomarkers in acute respiratory distress syndrome. Curr Opin Crit Care 2014, 20:47-55. 10.1097/MCC.0000000000000048, 24296379.
24. Hofmann MA, Drury S, Fu C, Qu W, Taguchi A, Lu Y, et al. RAGE mediates a novel proinflammatory axis: a central cell surface receptor for S100/calgranulin polypeptides. Cell 1999, 97:889-901. 10.1016/S0092-8674(00)80801-6, 10399917.
25. Kikkawa T, Sato N, Kojika M, Takahashi G, Aoki K, Hoshikawa K, et al. Significance of measuring S100A12 and sRAGE in the serum of sepsis patients with postoperative acute lung injury. Dig Surg 2010, 27:307-12. 10.1159/000313687, 20689292.
26. Wittkowski H, Sturrock A, van Zoelen MA, Viemann D, van der Poll T, Hoidal JR, et al. Neutrophil-derived S100A12 in acute lung injury and respiratory distress syndrome. Crit Care Med 2007, 35:1369-75. 10.1097/01.CCM.0000262386.32287.29, 17414728.
27. Lorenz E, Muhlebach MS, Tessier PA, Alexis NE, Duncan Hite R, Seeds MC, et al. Different expression ratio of S100A8/A9 and S100A12 in acute and chronic lung diseases. Respir Med 2008, 102:567-73. 10.1016/j.rmed.2007.11.011, 18164192.
28. Giri JG, Wells J, Dower SK, McCall CE, Guzman RN, Slack J, et al. Elevated levels of shed type II IL-1 receptor in sepsis. Potential role for type II receptor in regulation of IL-1 responses. J Immunol 1994, 153:5802-9. 7989776.
29. Martin P, Palmer G, Vigne S, Lamacchia C, Rodriguez E, Talabot-Ayer D, et al. Mouse neutrophils express the decoy type 2 interleukin-1 receptor (IL-1R2) constitutively and in acute inflammatory conditions. J Leukocyte Biol 2013, 94:791-802. 10.1189/jlb.0113035, 23817563.
30. Paine R, Standiford TJ, Dechert RE, Moss M, Martin GS, Rosenberg AL, et al. A randomized trial of recombinant human granulocyte-macrophage colony stimulating factor for patients with acute lung injury. Crit Care Med 2012, 40:90-7. 10.1097/CCM.0b013e31822d7bf0, 21926600.
31. Evans CR, Karnovsky A, Kovach MA, Standiford TJ, Burant CF, Stringer KA. Untargeted LC-MS metabolomics of bronchoalveolar lavage fluid differentiates acute respiratory distress syndrome from health. J Proteome Res 2014, 13:640-9. 10.1021/pr4007624, 24289193.
32. Mantovani A, Locati M, Vecchi A, Sozzani S, Allavena P. Decoy receptors: a strategy to regulate inflammatory cytokines and chemokines. Trends Immunol 2001, 22:328-36. 10.1016/S1471-4906(01)01941-X, 11377293.
33. Muschter S, Berthold T, Greinacher A. Developments in the definition and clinical impact of human neutrophil antigens. Curr Opin Hematol 2011, 18:452-60. 10.1097/MOH.0b013e32834babdd, 21912255.
34. Clemmensen SN, Bohr CT, Rorvig S, Glenthoj A, Mora-Jensen H, Cramer EP, et al. Olfactomedin 4 defines a subset of human neutrophils. J Leukoc Biol 2012, 91:495-500. 10.1189/jlb.0811417, 22187488.
35. Chesnutt AN, Matthay MA, Tibayan FA, Clark JG. Early detection of type III procollagen peptide in acute lung injury. Pathogenetic and prognostic significance. Am J Respir Crit Care Med 1997, 156:840-5. 10.1164/ajrccm.156.3.9701124, 9310002.
36. Dell'Angelica EC, Schleicher CH, Santome JA. Primary structure and binding properties of calgranulin C, a novel S100-like calcium-binding protein from pig granulocytes. J Biol Chem 1994, 269:28929-36. 7961855.
37. Yang Z, Tao T, Raftery MJ, Youssef P, Di Girolamo N, Geczy CL. Proinflammatory properties of the human S100 protein S100A12. J Leukoc Biol 2001, 69:986-94. 11404386.
38. McMahan CJ, Slack JL, Mosley B, Cosman D, Lupton SD, Brunton LL, et al. A novel IL-1 receptor, cloned from B cells by mammalian expression, is expressed in many cell types. EMBO J 1991, 10:2821-32. 1833184.
39. Colotta F, Dower SK, Sims JE, Mantovani A. The type II 'decoy' receptor: a novel regulatory pathway for interleukin 1. Immunol Today 1994, 15:562-6. 10.1016/0167-5699(94)90217-8, 7848516.
40. Penton-Rol G, Orlando S, Polentarutti N, Bernasconi S, Muzio M, Introna M, et al. Bacterial lipopolysaccharide causes rapid shedding, followed by inhibition of mRNA expression, of the IL-1 type II receptor, with concomitant up-regulation of the type I receptor and induction of incompletely spliced transcripts. J Immunol 1999, 162:2931-8. 10072543.
41. Orlando S, Matteucci C, Fadlon EJ, Buurman WA, Bardella MT, Colotta F, et al. TNF-alpha, unlike other pro- and anti-inflammatory cytokines, induces rapid release of the IL-1 type II decoy receptor in human myelomonocytic cells. J Immunol 1997, 158:3861-8. 9103454.
42. Knaus WA, Wagner DP, Draper EA, Zimmerman JE, Bergner M, Bastos PG, et al. The APACHE III prognostic system. Risk prediction of hospital mortality for critically ill hospitalized adults. Chest 1991, 100:1619-36. 10.1378/chest.100.6.1619, 1959406.